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Background: BAG3 gene mutations have been recently implicated as a novel cause of dilated cardiomyopathy
(DCM). Our aim was to evaluate the prevalence of BAG3 mutations in Polish patients with DCM and to search for
genotype-phenotype correlations.
Methods: We studied 90 unrelated probands by direct sequencing of BAG3 exons and splice sites. Large
deletions/insertions were screened for by quantitative real time polymerase chain reaction (qPCR).
Results: We found 5 different mutations in 6 probands and a total of 21 mutations among their relatives: the known
p.Glu455Lys mutation (2 families), 4 novel mutations: p.Gln353ArgfsX10 (c.1055delC), p.Gly379AlafsX45 (c.1135delG),
p.Tyr451X (c.1353C>A) and a large deletion of 17,990 bp removing BAG3 exons 3–4. Analysis of mutation positive
relatives of the probands from this study pooled with those previously reported showed higher DCM prevalence among
those with missense vs. truncating mutations (OR = 8.33, P = 0.0058) as well as a difference in age at disease onset
between the former and the latter in Kaplan-Meier survival analysis (P = 0.006). Clinical data from our study suggested
that in BAG3 mutation carriers acute onset DCM with hemodynamic compromise may be triggered by infection.
Conclusions: BAG3 point mutations and large deletions are relatively frequent cause of DCM. Delayed DCM onset
associated with truncating vs. non-truncating mutations may be important for genetic counseling.
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Dilated cardiomyopathy (DCM) is a major cause of
chronic heart failure and the most common indication for
cardiac transplantation [1]. In a substantial number of cases
DCM is familial with autosomal dominant inheritance.
Whereas a large number of genes have been shown
to harbor mutations causing DCM [2] novel disease
loci are continuously being reported. One interesting
gene which recently has been implicated as a novel
DCM locus is BAG3 [3,4].
BAG3 belongs to a family of co-chaperones playing an
anti-apoptotic role with their BAG domains binding* Correspondence: rploski@wp.pl
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article, unless otherwise stated.the ATPase domain of heat shock proteins 70
(Hsc70/Hsp70) [5]. BAG3 is expressed primarily in
skeletal muscle cells and cardiomyocytes, where it
localizes within the Z-disc and probably acts as a signaling
molecule [6]. Mice with homozygous knockout of the
BAG3 gene have degeneration of muscle fibers in
striated muscle with apoptosis leading to fulminant
skeletal myopathy and cardiomyopathy causing death
approximately four weeks after birth [6]. BAG3-null
zebrafish demonstrated myocardial changes resembling
human DCM [3]. Since BAG3 has an anti-apoptotic activity,
the DCM-associated BAG3 mutations may act through
increasing cardiomyocytes’ sensitivity to apoptosis as shown
experimentally for metabolic [7] or mechanical stress [8].
A specific BAG3 mutation virtually always occurring de
novo (Pro209Leu) causes a severe childhood myofibrillarntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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caused by other known BAG3mutations [9-11].
The purpose of our study was to evaluate the prevalence
of BAG3 mutations in Polish patients with DCM and to
search for genotype-phenotype correlations.
Methods
Patients and families
The study cohort was drawn from all index patients
referred for clinical DCM genetic testing from 2010 to
2013 to the Unit for Screening Studies in Inherited
Cardiovascular Diseases and involved 90 unrelated
probands with DCM (67 or 74.4% male). The pedigrees of
families are shown in Figure 1. DCM was diagnosed
according to the ESC criteria [12] with left ventricular ejec-
tion fraction below 45% and left ventricular end-diastolic
diameter exceeding 117% of value appropriate to age and
body surface area. In all probands coronary angiography,
or more recently coronary computed tomography angiog-
raphy (CTA) was performed. Data concerning the heart
transplant recipients were reviewed to confirm the
diagnosis of DCM prior to heart transplantation.
DCM was considered familial when more than one
member was affected after clinical, electrocardiographic
and echocardiographic evaluation of all the informed and
consenting relatives. Creatine phosphokinase (CPK) level
was obtained whenever possible. In addition, medical
records of hospitalized patients were reviewed, in particular
we reviewed: (1) histopathologic data of endomyocardial
biopsy in two DCM patients - in one patient biopsy was
performed based on clinical indications (acute onset heart
failure) and in the other two pieces of endomyocardial
tissue were obtained during ventricular assist device
implantation due to fulminant heart failure, (2) cardiovas-
cular magnetic resonance (CMR) data of one patient (CMR
performed due to clinical suspicion of myocarditis). All
patients and relatives gave written informed consent to
participate in the study in accordance with the Declaration
of Helsinki and study protocol was approved by the local
Bioethics Committee. Once a mutation was identified adult
first-degree relatives of the mutation carriers were offered
mutation screening. The clinical description of the DCM-1
family was reported previously [13,14]. A phenotypic
characteristic was updated to include additional family
members. In one subject (III-5) from the DCM-15 family
an additional permission from the Bioethics Committee
was obtained to confirm the presence of mutation in the
DNA extracted from myocardial tissue taken at the time of
ventricular assist device (VAD) implantation.
Screening for BAG3 mutations
DNA was extracted from the peripheral blood by phenol
extraction. We screened the entire coding region together
with splice sites of BAG3 by direct Sanger sequencing. Forall BAG3 exons PCR was carried out with primers listed
in Additional file 1: Table S1. The PCR conditions were:
5 min of initial denaturation at 95°C, followed by 32 cycles
of 30 sec at 95°C, 55 sec at 60-68°C, 1 min at 72°C
and final extension of 10 min at 72°C. PCR products were
examined on 2.5% agarose gels and then sequenced using a
3500×L Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA) and BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems) according to the manufacturer’s
instructions. The results were analyzed with Variant
Reporter 1.1 Software (Applied Biosystems).
Screening for large deletions in BAG3
The screening for large deletions in BAG3 was performed
by quantitative PCR (qPCR) using Applied Biosystems
7500 Real Time PCR System and MESA GREEN Master-
Mix Plus, Low ROX (Eurogentec, Belgium). The PCR
conditions were: 10 min of initial denaturation at 95°C,
followed by 40 cycles of 15 sec at 95°C and 1:45 min
at 60°C. Albumin gene (ALB) was used as a reference.
All qPCR analyses were run in duplicates. Copy number
was calculated by delta delta Ct method i.e. ΔΔCt = (Ct
BAG3 - Ct ALB)test - (Ct BAG3 - Ct ALB)wild type where Ct
denotes mean cycle number in which threshold value of
fluorescence was recorded for the BAG3 or ALB primers
for the reference (a sample without deletion, i.e. ‘wild type’)
and tested (‘test’) sample, respectively. For Ct determination
the default method available on the instrument was used.
ΔΔCt > 0.8 was regarded as indicative of deletion. Subse-
quent fine mapping of the detected deletion was performed
in a similar way using a stepwise approach. The sequences
of BAG3 and ALB primers used at both stages of analysis
are listed in Additional file 2: Table S2. Primers used for
final PCR-amplification and sequencing of the breakpoint
region were: BAG3intron2/3 5′TGC TCT CAA TTT CGA
GGT GA 3′ and BAG3del 5′ CGG GAG AAT CAT GAG
GTC AG 3′ (the forward and the reverse primer, respect-
ively). The same primers as those used for sequencing of
the breakpoint region were also used for screening of family
members for the presence of the deletion.
Statistical analysis
Statistical significance of difference in DCM prevalence
among subjects with truncating vs. non-truncating
BAG3 mutations was performed by Chi square test. Age at
DCM onset in these groups was analyzed by Kaplan-Meier
survival curves and Cox’s F-Test. All analyses were
performed using Statistica software package (StatSoft).
Results
Analysis of probands
Direct sequencing of the BAG3 coding sequence and splice
sites showed four different mutations in five DCM
families: known missense Glu455Lys mutation in 2 families
Figure 1 Pedigrees of families with BAG3 mutations: family DCM-1 - large deletion of exons 3–4, family DCM-15 - Gly379AlafsX45,
family DCM-16 - Glu455Lys, family DCM-84 - Tyr451X, family DCM-71 - Glu455Lys, family DCM-18 - Gln353ArgfsX10. Squares represent
males and circles represent females. An arrowhead denotes the proband. A diagonal line marks deceased individuals. Solid symbols denote dilated
cardiomyopathy. Open symbols with asterisk denote unaffected individuals with clinically normal echo/ecg. Other features are shown in box below.
The presence or absence of a BAG3 mutation is indicated by a + or− symbol, respectively; obligate carriers are noted in parenthesis (+).
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dicted to cause frameshifts: Gln353ArgfsX10 (c.1055delC)
(DCM-18), Gly379AlafsX45 (c.1135delG) (DCM-15), and a
novel Tyr451X (c.1353C>A) mutation predicted to insert a
premature stop codon (DCM-84). Each of the truncating
mutations occurred in a single family. Chromatograms
illustrating the novel mutations are shown in Figure 2.
None of the detected BAG3 mutations were found in
population databases.
To search for large deletions in BAG3 we performed
qPCR comparing dosage of DNA within BAG3 exons
with that a reference gene (albumin). In one sample
(proband from the DCM-1 family) using primers
RT_Exon3 and RT_Exon4.1 located in exons 3 and 4
respectively we observed shifts in amplification curves
consistent with presence of a heterozygous deletion
(ΔΔCt = 0.92).
Next, we carried out qPCR experiments aimed at
stepwise narrowing of the deleted region. Eight such
experiments were performed and they eventually allowed
to narrow down the deletion to a region sufficiently short
to design PCR primers likely to amplify the deletion
breakpoint. The PCR product was obtained and its iden-
tity was verified by sequencing which also demonstrated
that the deletion encompassed a region of 17,990 bp
including 3 and 4 exons of BAG3 and extending into the
telomeric end in the direction of the INPP5F gene
(Figure 2D). We noted that the 5 bp of the DNA sequence
directly adjacent to the centromeric end of the deleted
fragment was identical to the sequence at the telomeric
end of the deleted fragment (AGTGG in both cases,
Figure 2D).
The prevalence among probands of all detected BAG3
mutations was 6/90 or 6.7% with 95% confidence interval
from 3.1% to 13.8%.Figure 2 Chromatograms illustrating novel BAG3 mutations found. A
C - p.Tyr451X (c.1353C>A), D - large deletion of 17,990 bp removing BAG3Clinical and histopathological findings among the
probands
Among the six probands with BAG3 mutations one had
an acute onset with a fulminant course of the disease
(DCM-15 III-7) and died awaiting heart transplantation
(HTX) while on ventricular assist devices within three
months from the diagnosis. Three probands (DCM-18
III-2, DCM-1 IV-1, DCM-71 III-4) received HTX after
60, 108 or 196 months from the diagnosis, respectively.
Two probands experienced partial recovery: one remains
stable after 108 months with LVEF 36% and another one
with 2 months follow-up’ time experienced significant
improvement in LV systolic function (LVEF 51%) while on
standard treatment of heart failure. Clinical characteristics
of probands are given in Additional file 3: Table S3.
Histopathological analysis in patients with the
Glu455Lys variant (DCM-16 III-1) was performed within
one month after the onset of acute heart failure. The
findings were non specific with features of cellular
hypertrophy, myocardial cell degeneration and interstitial
fibrosis as usually found in DCM. In the specimen
from the patient with the Gly379AlafsX45 variant
(DCM-15 III-5) tissue severe myocytolysis with scarce
inflammatory infiltrate was found.
Analysis of family members – clinical findings
In addition to six probands we have identified 21
relatives with BAG3 mutations. Eleven (52.4%) of
these subjects had DCM with the mean age at onset
of 36 years (range 15–53). There were two deaths:
one female died suddenly at 58 years after 60 months
from the diagnosis and there was one heart failure
death at 42 years after 120 months from the diagnosis in a
male patient. Significant left ventricular dysfunction at the
end of follow-up with LVEF ≤ 45% was present in 9– p.Gln353ArgfsX10 (c.1055delC), B - p.Gly379AlafsX45, (c.1135delG),
exons 3–4, chromatogram shows breakpoint sequence.
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improvement in LV function was observed over the
follow-up while on standard treatment for heart failure.
Persistent normal LV function was found in 10 (47.6%)
carriers whose mean age was 29.2 years (range 20–53).
Clinical characteristics of relatives with BAG3 mutations
are given in Additional file 3: Table S3.
CMR study in DCM-15 III-2 (Gly379AlafsX45),
performed within one month after the onset of
symptoms showed dilated hypocontractile left ventricle
and the presence of CMR diagnostic criteria for myocarditis
[15]. In particular, T2-weighted images demonstrated
global myocardial signal intensity (SI) increase (>2) in
comparison to skeletal muscle indicating global edema
(Additional file 4: Figure S1A). There was also an increased
global myocardial early gadolinium enhancement ratio (>4)
in comparison to skeletal muscle in* gadolinium-
enhanced T1-weighted images indicating global myocardial
hyperemia. Late gadolinium enhancement (LGE) revealed
intramyocardial foci in the interventricular septum and at
the low junction point of the right and left ventricle indi-
cating myocardial fibrosis (Additional file 4: Figure S1B).
At the time of CMR study, serological examinations
showed positive serum IgM Lyme titres and borderline
IgG, positive IgG antyParvovirus B19 titres and detectable
human herpes virus 6 (HHV6) genome in the serum. The
patient received gammaglobulin 0.1 g/kg i.v. along
with doxycycline 100 mg PO bid for 21 days leading to
substantial clinical improvement (a rise in LVEF up to 36%).
Analysis of family members – genotype dependent
penetrance of BAG3 related DCM
All subjects with BAG3 mutations who were DCM free had
truncating mutations whereas all those with missense
mutations were affected (Table 1). A trend for higher DCM
prevalence among those with missense BAG3 mutations
was also found on reanalysis of data previously reported for
mutation positive family members of probands with BAG3
related DCM [3,4]. When our data were combined withTable 1 Presence of DCM among subjects with truncating




N (%) N (%)
This study Yes 8 (44) 10 (56)
No 3 (100) 0
Previous studies Yes 19 (79) 5 (21)
No 12 (92) 1 (8)
Combined* Yes 27 (64) 15 (36)
No 15 (94) 1 (6)
*OR = 8.33, P = 0.045 (P = 0.0058 after excluding a DCM free 7 year old child as
non-informative, Fisher exact test), OR calculated for presence of DCM among
non-truncating vs. truncating BAG3 mutations.data reported previously [3,4] there was a statistically
significant difference indicating higher prevalence of DCM
among those with non-truncating vs. truncating BAG3
mutations (OR = 8.33, P = 0.045, Table 1). The association
was even stronger (P = 0.0058) when a healthy child aged 7
reported by Villard et al. was excluded from analysis
as uninformative due to young age (Table 1).
These results suggested that missense vs. truncating
BAG3 mutations could be associated with earlier disease
onset and/or lower penetrance or just age difference
between the groups. To study this further we analyzed
age at DCM onset in the two groups by Kaplan-Meier
survival analysis. Figure 3 shows time to DCM onset in
family members of the probands stratified by the mutation
category (subjects from the present study were pooled with
those reported previously [3,4]). As can be seen, whereas by
the age of 70 the disease penetrance is apparently 100%, by
the age of 50 years the prevalence of DCM among those
with non-truncating vs. truncating BAG3 mutations
differs (~90% vs. ~55%, respectively, Figure 3). The
difference between the two groups in DCM free survival
was statistically significant (P = 0.006, Cox’s F-Test).
Discussion
While studying a cohort of 90 adult unrelated DCM
patients and their relatives we found BAG3 mutations in
6 probands and 21 family members. Four of the observed
mutations were novel: Gln353ArgfsX10 (c.1055delC),
Gly379AlafsX45, (c.1135delG), Tyr451X (c.1353C>A) and
a large deletion removing 17,990 bp. Analysis of affection
status in BAG3 mutations carriers among relatives of the
probands from our cohort together with those reported
previously [3,4] showed difference in age related penetrance
which, interestingly, suggested later onset of disease in
those with non-truncating vs. truncating mutations.
The BAG3 Glu455Lys (rs397516881) has been reported
previously as pathogenic although this was based on a
single report [3,4] and the ClinVar database [16] describes
the variant as having uncertain significance. The conclusion
on Glu455Lys pathogenicity was based on a single family in
which this variant was found in five individuals four of
whom had DCM [3,4]. Our finding of rs397516881 in two
apparently unrelated DCM probands and three affected
family members together with its lack in NHLBI GO
exome sequencing project (ESP) [17], 1000 genomes
databases [18] and our in-house exome database of 250
Poles argues for genuine association of BAG3 Glu455Lys
with DCM. However, this conclusion would certainly be
strengthened by additional data from other populations.
The Gln353ArgfsX10 (c.1055delC), Gly379AlafsX45
(c.1135delG) and the 17,990 bp deletion removing exons
3–4 are likely to be pathogenic as they are predicted to
remove a larger C terminal part of the BAG3 protein
than the two previously reported pathogenic BAG3



























DCM  no DCM
Figure 3 Figure Kaplan-Meier survival curves for relatives of probands with truncating and non-truncating BAG3 mutations. (P = 0.006,
Cox’s F-Test, data from the present study pooled with data from 2 previous studies [3,4]).
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argument does not apply to Tyr451X which is the
most C terminal (the least truncating) BAG3 mutation
reported so far. However, Tyr451X is also likely to be
pathogenic as it removes more than half of the single
BAG domain present in the BAG3 protein. The deleted
part contains whole alpha3 helix and a significant part of
the alpha2 helix, both of which are responsible for binding
between BAG3 and Hsc710/Hsp70 [19]. The part of
alpha2 and the whole alpha3 helix which are deleted by
Tyr451X mutation contain numerous aminoacids highly
conserved both among BAG domains of different
human BAG proteins [19] and between BAG3 proteins of
different species (Additional file 5: Figure S2). Finally,
the BAG3 Tyr451X mutation, similar as Gln353ArgfsX10
(c.1055delC), Gly379AlafsX45 (c.1135delG), has not been
observed in NHLBI GO exome sequencing project (ESP)
[17], 1000genomes database [18], ClinVar databases [16]
or our in-house exome database of 250 Poles. Whereas
all these findings suggest pathogenicity, as recently
emphasized for other variants [20,21], more data is
needed for a firm conclusion.
Among the novel BAG3 mutations the most interest-
ing is the large deletion of 17,990 bp which removes
exons 3–4 and a chromosome fragment extending in the
direction of the INPP5F gene. This deletion, together
with the deletion of 8,733 bp described by Norton et al.
[3] suggests that the 3′ part of the BAG3 locus may be
prone to structural rearrangements. The 17,990 bp deletion
probably originated due to microhomology at the
breakpoints and thus may be recurrent [22]. These
observations highlight the necessity for screening BAG3for copy number variations (CNV) variants in addition to
point mutations.
The prevalence of BAG3 defects in our cohort was
relatively high (6/90 or 6.7%) being comparable to the
prevalence of mutations in LMNA (~6%) which has been
regarded as the most frequently mutated locus in DCM
[23,24]. Thus, the BAG3 gene emerges as a major DCM
locus. Although its role is clearly smaller than that of
TTN, whose mutations have recently been shown to
occur in up to 25% of DCM patients [25] our results
indicate that, at least in Polish population, a systematic
screening of BAG3 should be offered to DCM patients.
The findings that truncating BAG3 mutations cause
disease with later onset than missense variants may be
important for genetic counselling. Although it should be
confirmed by a study specifically addressing disease
severity, our results suggest that missense BAG3 mutations
may have a stronger pathogenic effect than the truncating
variants. Interestingly, that would contrast with observa-
tions for the LMNA gene whose truncating variants were
recently associated with a more severe DCM [26]. As
shown for the LMNA gene [27], a likely main effect of trun-
cating mutations is the loss of function, whereas missense
variants may in addition (or alternatively) exert dominant
negative effects. Pathogenicity of BAG3 haploinsufficiency
is supported by DCM association shown for a number of
truncating variants, in particular the severely truncating
BAG3 Arg90X mutation [3]. However, earlier onset of
DCM suggestive of a more severe phenotype associ-
ated with non-truncating mutations found in our study
indicates that at least some BAG3 missense variants exert
dominant-negative effects. This notion is consistent
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myopathy) consistently observed in patients with the
BAG3 p.Pro209Leu mutation [9-11].
Clinical data from our study suggest that in presence
of BAG3 defects stress may trigger acute onset DCM
with hemodynamic compromise, which is consistent
with in vitro studies implicating BAG3 in the control of
apoptosis and response to stress stimuli [7,8]. A BAG3
mutation carrier with history of acute heart failure
(DCM-15 III-2) fulfilled CMR diagnostic criteria for
myocarditis with serological evidence of acute Lyme
disease and past Parvovirus B19 infection, and a detectable
HHV6 genome in the blood. Intramyocardial foci of late
gadolinium enhancement in the interventricular septum
were previously observed in patients with myocarditis asso-
ciated with human HHV6 infection or Lyme disease
[12,28-30]. Moreover, all severely affected BAG3 mutation
carriers of the DCM-18 family had disease onset related to
the influenza of 1988 along with two of deceased first-
degree members of the family who developed progressive
heart failure leading to death. Furthermore, all subjects
with BAG3 mutations who had acute onset of heart
failure following viral-like illness had very low LVEF
(10-22%), that is consistent with poor response to any
pathogen-related stress.
Conclusions
In conclusion, by studying Polish patients we found that
BAG3 mutations are relatively frequent cause of DCM.
We report four novel pathogenic BAG3 variants including
a large deletion and show, for the first time, that truncating
BAG3 variants are associated with DCM characterized by
later onset than missense variants. Clinical data from our
study suggest that in BAG3 mutation carriers infection
may trigger acute onset DCM with hemodynamic
compromise. Despite the limitations of our study such as
relatively small number of subjects and a retrospective
design our results add to the knowledge on BAG3 related
diseases and, if replicated in additional cohorts, may be
important for genetic counseling.
Additional files
Additional file 1: Table S1. Primers used for mutation screening of
BAG3 coding sequence and the splice sites.
Additional file 2: Table S2. Primers used for screening for large BAG3
deletions (A) and for subsequent fine mapping of the deletion region
(B, listed in order of use).
Additional file 3: Table S3. Clinical characteristics of probands and
relatives. Description of data: Legend: Fam - Family; Sub - Subject; A,g - Age at
genetic inquest; Sex - sex (M-male, F-female); R - Relatives (1-1st degree, 2-2nd
degree, 3-3rd degree); A,d - Age at diagnosis/at screening; Phen – phenotype
(DCM/ N-normal heart); EF – LVEF; N,os - NYHA at onset of symptoms/at
screening; E/a - ECG/arrhythmia; T,d - Time from diagnosis (months);
EDD,f-p - LVEDD (mm) at last follow-up; EF,f-p - LVEF (%) at last follow-up;
I/P - ICD/PM; Additional – comments/co-existing disease/family history;(*) - DNA available, died earlier; (†) - DNA extracted from the endomyocardial
tissue; ACE-I - angiotensin converting enzyme inhibitors; AII - angiotensin II
blockers; a-v - atrio-ventricular; BB - beta-blockers; DOE – dyspnea on effort;
ECG - standard 12-lead electrocardiogram; FA/VA - atrial fibrillation/atrial
flutter; HF - heart failure; HTN - hypertension; HTX - heart transplantation;
ICD - internal cardioverter defibrillator; LBBB - left bundle branch block;
LV - left ventricular; LVEDD - left ventricular enddiastolic dimension; LVEF - left
ventricular ejection fraction; MI - myocardial infarction; nsVT - nonsustained
ventricular tachycardia; P - palpitations; PM - pacemaker, QTc - corrected QT
interval; SCD - sudden cardiac death; SR - sinus rhythm; VAD - ventricular
assist device; VEX - ventricular extrasystole).
Additional file 4: Figure S1. Cardiovascular magnetic resonance images
demonstrating signs of myocarditis in patient DCM-15 II-2. Description of
data: T2-weighted image in short axis demonstrating global myocardial
edema (increased signal intensity of the myocardium in comparison to the
skeletal muscle), B) short axis image showing intramyocardial foci of late
gadolinium enhancement (arrows).
Additional file 5: Figure S2. The highly conserved sequence of BAG3
exon 4 of different species with marked BAG domain. Description of data:
Black arrow indicates the position of Tyr451X mutation. The color
saturation reflects the conservation of amino acid. The red frame outlines
human BAG3 protein ID ENSP00000358081.
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